New pill slows lung cancer brain spread in major trial

NCT ID NCT03653546

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times

Summary

This study tested a new oral drug, AZD3759, against standard targeted therapies for people with advanced lung cancer that has spread to the brain. About 492 adults with a specific gene mutation (EGFR) took either the new drug or a standard one. The goal was to see if AZD3759 could better delay cancer growth, especially in the brain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • China site

    Hefei, Anhui, 230001, China

  • China site

    Chongqing, China, 400037, China

  • China site

    Fuzhou, Fujian, 350014, China

  • China site

    Xiamen, Fujian, 361003, China

  • China site

    Guangzhou, Guangdong, 510080, China

  • China site

    Guangzhou, Guangdong, 510180, China

  • China site

    Haerbin, Heilongjiang, 150081, China

  • China site

    Zhengzhou, Henan, 450008, China

  • China site

    Zhengzhou, Henan, 450052, China

  • China site

    Wuhan, Hubei, 430022, China

  • China site

    Wuhan, Hubei, 430030, China

  • China site

    Wuhan, Hubei, 430079, China

  • China site

    Yichang, Hubei, 443003, China

  • China site

    Changsha, Hunan, 410013, China

  • China site

    Nanjing, Jiangsu, 210002, China

  • China site

    Nanjing, Jiangsu, 210009, China

  • China site

    Suzhou, Jiangsu, 215004, China

  • China site

    Wuxi, Jiangsu, 214062, China

  • China site

    Xuzhou, Jiangsu, 221002, China

  • China site

    Yangzhou, Jiangsu, 225001, China

  • China site

    Changchun, Jilin, 130012, China

  • China site

    Changchun, Jilin, 130021, China

  • China site

    Xi'an, Shaanxi, 710061, China

  • China site

    Linyi, Shandong, 276000, China

  • China site

    Weifang, Shandong, 261000, China

  • China site

    Yantai, Shandong, 264000, China

  • China site

    Chengdu, Sichuan, 610041, China

  • China site

    Kunming, Yunnan, 650118, China

  • China site

    Hangzhou, Zhejiang, 310003, China

  • China site

    Hangzhou, Zhejiang, 310022, China

  • China site

    Hangzhou, Zhejiang, 311100, China

  • China site

    Beijing, 100021, China

  • China site

    Beijing, 100071, China

  • China site

    Beijing, 100142, China

  • China site

    Beijing, 100730, China

  • China site

    Chongqing, 400030, China

  • China site

    Chongqing, 400042, China

  • China site

    Shanghai, 200030, China

  • China site

    Shanghai, 200032, China

  • China site

    Tianjin, 300052, China

  • China site 0123

    Jinan, Shandong, 250117, China

  • Korea Site

    Jungbuk, 28644, South Korea

  • Korea Site

    Seoul, 03080, South Korea

  • Korea Site

    Seoul, 06351, South Korea

  • Korea site

    Daegu, 42415, South Korea

  • Korea site

    Gyeonggi-do, 16247, South Korea

  • Korea site

    Gyeongsang, 52727, South Korea

  • Korea site

    Incheon, 21565, South Korea

  • Korea site

    Seoul, 05368, South Korea

  • Korea site

    Seoul, 06591, South Korea

  • Korea site

    Seoul, 07061, South Korea

  • Korea site

    Suwon, 16499, South Korea

  • Korea site

    Ulsan, 44033, South Korea

  • Singapore site

    Singapore, 308433, Singapore

  • Taiwan site

    Taichung, 407, Taiwan

  • Taiwan site

    Tainan, 704, Taiwan

  • Taiwan site

    Taipei, 100, Taiwan

  • Taiwan site

    Taoyuan District, 333, Taiwan

Conditions

Explore the condition pages connected to this study.